PTEN and prostate carcinoma: The administration of the tyrosine kinase inhibitor cabozantinib resulted in the clearance of invasive prostate cancer of Pten/Tp53-deficient (prostate-specific knockout) mouse model by recruiting neutrophils to the tumor [42].